Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced RCC
NCT07188896Phase 2Recruiting
- Start
- Apr 2026
- Primary completion
- Nov 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fianlimab and cemiplimab in renal cell carcinoma (RCC) (3 arms). Primary endpoint: Objective Response Rate at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
fianlimabcemiplimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07188896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07188896.